HOME >> BIOLOGY >> NEWS
'Modular' leukemia drug shows promise in early testing

COLUMBUS , Ohio -- A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and kill them. The agent works both by triggering the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked equally as well as the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

Our findings have significant implications for the treatment of CLL and related malignancies, says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, the findings indicate that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein.

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that this self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires en
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
28-Jun-2007


Page: 1 2

Related biology news :

1. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
2. Scientists gain important insights into acute promyelocytic leukemia
3. Researchers discover inherited mutation for leukemia
4. Inherited genes linked to toxicity of leukemia therapy
5. Unstable leukemia stem cells may predispose patients to drug resistance
6. Tree rings show elevated tungsten coincides with Nevada leukemia cluster
7. Cancer scientists create human leukemia process to map how disease begins, progresses
8. Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
9. Knocking out survival protein could aid leukemia treatment
10. Massey researchers induce cell death in leukemia
11. Progress toward a targeted therapy for a specific form of leukemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/6/2019)... , ... February 04, 2019 , ... ... new Explorer™ story which provides insights to help individuals understand how the gut ... cardiovascular wellness. , After individuals eat foods that contain choline and L-carnitine, ...
(Date:2/2/2019)... ... January 31, 2019 , ... Aperio ... customizable clinical research services across multiple therapeutic areas, announced an Innovation Partner ... life science entrepreneurs in the Research Triangle region of North Carolina. ...
(Date:1/25/2019)... ... January 24, 2019 , ... GrowthZone, Inc., ... Survey. The report indicates membership growth in some sectors and decreasing membership among ... received responses from over 500 association professionals across North America. , “This ...
Breaking Biology News(10 mins):
(Date:1/15/2019)... ... 2019 , ... Personalized treatment plans may extend life expectancy for early-stage kidney ... study published in the journal Radiology. , Kidney, or renal, tumors are often ... procedure in which the tumor and part of the kidney are removed. However, some ...
(Date:1/11/2019)... ... ... Drawing on over 22 years of software development expertise, the live webinar ... the key lessons that have driven customer satisfaction with their eClinical suite. Explore the ... how to ensure that you continue to be able to take advantage of the ...
(Date:1/10/2019)... ... 2019 , ... VGI Medical was founded in 2007 based on an invention ... the market including VerteLoc, CerLoc, SiJoin and VerteLP. The VerteLoc and CerLoc systems are ... dual geometric design to limit motion of the affected spinal segment. Applying the principles ...
(Date:1/7/2019)... (PRWEB) , ... January 07, 2019 , ... ... 1 clinical trials of its Parkinson's Disease drug candidate, code-named "KM-819." KM-819 ... Parkinson's Disease. The trial took place in South Korea. , This Phase ...
Breaking Biology Technology:
Cached News: